

Attorney's Docket No. 35721/265190

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Kaltenboeck *et al.* Confirmation No.: Not yet assigned  
Appl. No.: 10/632,426 Art Unit: Not yet assigned  
Filed: August 1, 2003 Examiner: Not yet assigned  
For: MOUSE DISEASE MODEL FOR EVALUATION OF PROPHYLACTIC  
AND THERAPEUTIC TREATMENTS FOR CHLAMYDIA

October 28, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**


Sir:

Attached is a list of documents on form PTO-1449. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

  
W. Murray Spruill  
Registration No. 32,943

| CERTIFICATE OF MAILING   |  |
|--|--|
| <b>CUSTOMER NO. 00826</b><br><b>ALSTON &amp; BIRD LLP</b><br>Bank of America Plaza<br>101 South Tryon Street, Suite 4000<br>Charlotte, NC 28280-4000<br>Tel Raleigh Office (919) 862-2200<br>Fax Raleigh Office (919) 862-2260 | I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:<br>Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,<br>on October 28, 2003<br><br>Lynda-Jo Pixley |

Substitute for form 1449/PTO  
(Revised 04/2003)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

### Complete if Known

Application Number 10/632,426  
Filing Date August 1, 2003  
First Named Inventor Kaltenboeck  
Group Art Unit Not yet assigned  
Examiner Name Not yet assigned  
Attorney Docket Number 35721/265190

### U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Document Number<br>Number - Kind Code (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages of Relevant Figures<br>Appear |
|--------------------|----------|--|--------------------------------|--|---|
|                    | 1        | US-5,324,668                                     | 06-28-1994                     | Macri.   |   |
|                    |          |  |                                |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document<br>Country Code - Number Kind Code<br>(if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | English<br>Language<br>Translation<br>Attached |
|-------------------|----------|--|--------------------------------|---|--|--|
|                   |          |  |                                |   |  |  |
|                   |          |  |                                |   |  |  |

### OTHER DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | English Language<br>Translation<br>Attached |
|-------------------|----------|---|---|
|                   | 2        | ALLIONE, <i>et al.</i> , "Nitric Oxide Suppresses Human T Lymphocyte Proliferation Through IFN- $\gamma$ -Dependent and IFN- $\gamma$ -Independent Induction of Apoptosis," <i>The Journal of Immunology</i> , 1999, pp. 4182-4191, Vol. 163.                   |   |
|                   | 3        | CHANG, <i>et al.</i> , "Arginase Modulates Nitric Oxide Production in Activated Macrophages," <i>Am. J. Physiol.</i> , 1998, pp. H342-H348.   |   |
|                   | 4        | DALTON, <i>et al.</i> , "Interferon $\gamma$ Eliminates Responding CD4 T Cells during Mycobacterial Infection by Inducing Apoptosis of Activated CD4 T Cells," <i>J. Exp. Med.</i> , 2000, pp. 117-122, Vol. 192(1).  |   |
|                   | 5        | DETMERS, <i>et al.</i> , "Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice," <i>The Journal of Immunology</i> , 2000, pp. 3430-3435, Vol. 165.   |   |
|                   | 6        | DIEFENBACH, <i>et al.</i> , "Requirement for Type 2 NO Synthase for IL-12 Signaling in Innate Immunity," <i>Science</i> , 1999, pp. 951-955, Vol. 284.  |   |
|                   | 7        | GANTT, <i>et al.</i> , "Oxidative Responses of Human and Murine Macrophages During Phagocytosis of <i>Leishmania chagasi</i> ," <i>The Journal of Immunology</i> , 2001, pp. 893-901, Vol. 167.   |   |
|                   | 8        | GOTOH, T. and MORI, M., "Arginase II Downregulates Nitric Oxide (NO) Production and Prevents NO-mediated Apoptosis in Murine Macrophage-derived RAW 264.7 Cells," <i>The Journal of Cell Biology</i> , 1999, pp. 427-434, Vol. 144, No. 3.                      |   |

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449/PTO  
(Revised 04/2003)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

|                    |    |   |                          |                        |              |
|--------------------|----|---|--------------------------|------------------------|--------------|
|                    |    |   | <b>Complete if Known</b> |                        |              |
|                    |    |   | Application Number       | 10/632,426             |              |
|                    |    |   | Filing Date              | August 1, 2003         |              |
|                    |    |   | First Named Inventor     | Kaltenboeck            |              |
|                    |    |   | Group Art Unit           | Not yet assigned       |              |
|                    |    |   | Examiner Name            | Not yet assigned       |              |
| Sheet              | 2  | of  | 3                        | Attorney Docket Number | 35721/265190 |
|                    | 9  | GUO, <i>et al.</i> , "Molecular Mechanisms of Increased Nitric Oxide (NO) in Asthma: Evidence for Transcriptional and Post-Translational Regulation of NO Synthesis," <i>The Journal of Immunology</i> , 2000, pp. 5970-5980, Vol. 164.   |                          |                        |              |
|                    | 10 | HERRICK, C.A. and BOTTOMLY, K., "To Respond or Not To Respond: T Cells in Allergic Asthma," <i>Nature Reviews/Immunology</i> , 2003, pp. 1-8, Vol. 3.   |                          |                        |              |
|                    | 11 | HOLLAND, <i>et al.</i> , "Conjunctival Scarring in Trachoma Is Associated with Depressed Cell-Mediated Immune Responses to Chlamydial Antigens," <i>The Journal of Infectious Diseases</i> , 1993, pp. 1528-1531, Vol. 168.   |                          |                        |              |
|                    | 12 | HU, <i>et al.</i> , "The Artherogenic Effects of Chlamydia are Eependent on Serum Cholesterol and Specific to <i>Chlamydia pneumoniae</i> ," <i>Journal of Clinical Investigation.</i> , 1999, pp. 747-753, Vol. 103(5).  |                          |                        |              |
|                    | 13 | HUANG, <i>et al.</i> , "Nitric Oxide Regulates Th1 Cell Development Through the Inhibition of IL-12 Synthesis by Macrophages," <i>Eur. J. Immunol.</i> , 1998, pp. 4062-4070, Vol. 28.  |                          |                        |              |
|                    | 14 | HUANG, <i>et al.</i> , "IL-12 Administered During <i>Chlamydia psittaci</i> Lung Infection in Mice Confers Immediate and Long-Term Protection and Reduces Macrophage Inflammatory Protein-2 Level and Neutrophil Infiltration in Lung Tissue," <i>The Journal of Immunology</i> , 1999, pp. 2217-2226, Vol. 162.  |                          |                        |              |
|                    | 15 | HUANG, <i>et al.</i> , "The Quantity of Nitric Oxide Released by Macrophages Regulates <i>Chlamydia</i> -induced Disease," <i>PNAS</i> , 2002, pp. 3914-3919, Vol. 99(6).   |                          |                        |              |
|                    | 16 | IGIETSEME, <i>et al.</i> , "Resolution of Murine Chlamydial Genital Infection by the Adoptive Transfer of a Biovar-Specific, TH <sub>1</sub> Lymphocyte Clone," <i>Regional Immunology</i> , 1993, pp. 317-324, Vol. 5.   |                          |                        |              |
|                    | 17 | IGIETSEME, <i>et al.</i> , "Chlamydial Infection in Inducible Nitric Oxide Synthase Knockout Mice," <i>Infection and Immunity</i> , 1998, pp. 1282-1286, Vol. 66(4).  |                          |                        |              |
|                    | 18 | MORI, M. and GOTOH, T., "Relationship between Arginase Activity and Nitric Oxide Production," Chapter 12, <i>Nitric Oxide Biology and Pathobiology</i> , 2000, Chapter 12, pp.199-208.  |                          |                        |              |
|                    | 19 | JACKSON, <i>et al.</i> , "Specificity of Detection of <i>Chlamydia pneumoniae</i> in Cardiovascular Atheroma," <i>American Journal of Pathology</i> , 1997, pp. 1785-1790, Vol. 150(5).   |                          |                        |              |
|                    | 20 | KALTENBÖCK, <i>et al.</i> , "Genetically Determined Vigorous Innate Immunity is Associated with Protection Against Primary Chlamydial Lung Infection in Mice, but with Profound Disease Exacerbation in Reinfection," <i>Chlamydial Infections</i> , Proceedings of the Ninth International Symposium on Human Chlamydial Infection, June 21-26, 1998, pp. 403-406. |                          |                        |              |
|                    | 21 | LYONS, <i>et al.</i> , "Molecular Cloning and Functional Expression of an Inducible Nitric Oxide Synthase from a Murine Macrophage Cell Line," <i>The Journal of Biological Chemistry</i> , 1992, pp. 6370-6374, Vol. 267(9).   |                          |                        |              |
|                    | 22 | MACMICKING, <i>et al.</i> , "Nitric Oxide and Macrophage Function," <i>Annu. Rev. Immunol.</i> , 1997, pp. 323-350, Vol. 15.  |                          |                        |              |
|                    | 23 | MAGEE, <i>et al.</i> , " <i>Chlamydia trachomatis</i> Pneumonia in the Severe Combined Immunodeficiency (SCID) Mouse," <i>Regional Immunology</i> , 1993, pp. 305-311, Vol. 5(6).   |                          |                        |              |
|                    | 24 | MILLS, <i>et al.</i> , "M-1/M-2 Macrophages and the Th1/Th2 Paradigm," <i>The Journal of Immunology</i> , 2000, pp. 6166-6173, Vol. 164.  |                          |                        |              |
|                    | 25 | MOAZED, <i>et al.</i> , "Evidence of Systemic Dissemination of <i>Chlamydia pneumoniae</i> via Macrophages in the Mouse," <i>The Journal of Infectious Diseases</i> , 1998, pp. 1322-1325, Vol. 177.  |                          |                        |              |
| Examiner Signature |    |   |                          | Date Considered        |              |

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO  
(Revised 04/2003)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

|                    |  |                 |   |  |
|--------------------|--|-----------------|---|--|
| Sheet 3 of 3       |  |                 | <b>Complete if Known</b><br>Application Number 10/632,426<br>Filing Date August 1, 2003<br>First Named Inventor Kaltenboeck<br>Group Art Unit Not yet assigned<br>Examiner Name Not yet assigned<br>Attorney Docket Number 35721/265190 |  |
| 26                 | MOAZED, <i>et al.</i> , "Chlamydia pneumoniae Infection Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice," <i>The Journal of Infectious Diseases</i> , 1999, pp. 238-241, Vol. 180.   |                 |   |  |
| 27                 | MORRISON, <i>et al.</i> , "Gene Knockout Mice Establish a Primary Protective Role for Major Histocompatibility Complex Class II-Restricted Responses in <i>Chlamydia trachomatis</i> Genital Tract Infection," <i>Infection and Immunity</i> , 1995, pp. 4661-4668, Vol. 63(12). |                 |   |  |
| 28                 | MUNDER, <i>et al.</i> , "Th1/Th2-Regulated Expression of Arginase Isoforms in Murine Macrophages and Dendritic Cells," <i>The Journal of Immunology</i> , 1999, pp. 3771-3777, Vol. 163.   |                 |   |  |
| 29                 | OSWALD, <i>et al.</i> , "Low Response of BALB/c macrophages to Priming and Activating Signals," <i>Journal of Leukocyte Biology</i> , 1992, pp. 315-322, Vol. 52.  |                 |   |  |
| 30                 | PERRY, <i>et al.</i> , "Neither Interleukin-6 nor Inducible Nitric Oxide Synthase is Required for Clearance of <i>Chlamydia trachomatis</i> from the Murine Genital Tract Epithelium," <i>Infection and Immunity</i> , 1998, pp. 1265-1269, Vol. 66(3).                          |                 |   |  |
| 31                 | RAMSEY, <i>et al.</i> , "Chlamydia trachomatis Persistence in the Female Mouse Genital Tract: Inducible Nitric Oxide Synthase and Infection Outcome," <i>Infection and Immunity</i> , 2001, pp. 5131-5137, Vol. 69(8).   |                 |   |  |
| 32                 | RANK, R.G., "Models of Immunity," <i>Chlamydia: Intracellular Biology, Pathogenesis, and Immunity</i> , 1999, Chapter 9, pp. 239-295.  |                 |   |  |
| 33                 | ROSS, R., "Atherosclerosis – An Inflammatory Disease," <i>Mechanisms of Disease</i> , 1999, pp. 115-126, Vol. 340(2).  |                 |   |  |
| 34                 | ROTTENBERG, <i>et al.</i> , "Role of Innate and Adaptive Immunity in the Outcome of Primary Infection with <i>Chlamydia pneumoniae</i> , as Analyzed in Genetically Modified Mice," <i>The Journal of Immunology</i> , 1999, pp. 2829-2836, Vol. 162.                            |                 |   |  |
| 35                 | SCHACHTER, J., "Infection and Disease Epidemiology," <i>Chlamydia: Intracellular Biology, Pathogenesis, and Immunity</i> , 1999, Chapter 6, pp. 139-169.   |                 |   |  |
| 36                 | SCHWACHA, M.G. and EISENSTEIN, T.K., "Interleukin-12 is Critical for Induction of Nitric Oxide-Mediated Immunosuppression following Vaccination of Mice with Attenuated <i>Salmonella typhimurium</i> ," <i>Infection and Immunity</i> , 1997, pp. 4897-4903, Vol. 65(12).       |                 |   |  |
| 37                 | SCHWACHA, <i>et al.</i> , "Salmonella typhimurium Infection in Mice Induces Nitric Oxide-Mediated Immunosuppression through a Natural Killer Cell-Dependent Pathway," <i>Infection and Immunity</i> , 1998, pp. 5862-5866, Vol. 66(12).  |                 |   |  |
| 38                 | STEVENSON, <i>et al.</i> , "Genetic Linkage of Resistance to <i>Listeria Monocytogenes</i> with Macrophage Inflammatory Responses," <i>The Journal of Immunology</i> , 1981, pp. 402-407, Vol. 127(2).   |                 |   |  |
| 39                 | TEWS, J.K. and HARPER, A.E., "Tissue Amino Acids in Rats Fed Norleucine, Norvaline, Homoarginine or Other Amino Acid Analogues," <i>J. Nutr.</i> , 1986, pp. 1464-1472, Vol. 116(8).   |                 |   |  |
| 40                 | WILTSHIRE, <i>et al.</i> , "Genome-wide Single-nucleotide Polymorphism Analysis Defines Haplotype Patterns in Mouse," <i>PNAS</i> , 2003, pp. 3380-3385, Vol. 100(6).  |                 |   |  |
| 41                 | WRIGHT, <i>et al.</i> , "Infectious Agents Are Not Necessary for Murine Atherogenesis," <i>J. Exp. Med.</i> , 2000, pp. 1437-1441, Vol. 191(8).  |                 |   |  |
| 42                 | XIE, <i>et al.</i> , "Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages," <i>Science</i> , 1992, pp. 226-228, Vol. 256.   |                 |   |  |
| Examiner Signature |  | Date Considered |   |  |

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.